# Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

> **NCT04948333** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 199 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** ABL001 40mg BID
- **DRUG:** ABL001 80mg QD
- **DRUG:** ABL001 200mg QD

## Key facts

- **NCT ID:** NCT04948333
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-13
- **Primary completion:** 2024-03-12
- **Final completion:** 2026-02-25
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948333, "Asciminib Treatment Optimization in ≥ 3rd Line CML-CP". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04948333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*